Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Role and mechanism of YAP1 in pan-cancer

View through CrossRef
Abstract Backgrounds and aims: Cancers threaten health and life of patients with tumors. It is important to diagnose and treat various tumors as early as possible. However, there is limited early biomarkers for cancers. Yes-associated protein 1 (Yap1) is involved in the Hippo signaling pathway, and thus regulating development and cell growth. Yap1’s role in pan-cancer remains to be investigated. The objective of the present investigation was to explore the possible role and mechanism of Yap1 in pan-cancer. Methods Timer2.0 and GEPIA were employed to analyze the expression of YAP1 in cancerous tissues and controls; HPA was used to study the expression of YAP1 in different tissues and subcellular location; for survival analysis, GEPIA, the HPA, and KM plotter were utilized to generate survival curves, evaluating the prognostic significance of YAP1 expression; cBioPortal was used to investigate the mutation frequency and genetic alterations of YAP1; AlphaFold was applied to predict the structure of Yap1 and identify potential pathogenic sites, while PhosphoNet helped in predicting and analyzing phosphorylation sites of Yap1; the STRING was employed to explore Yap1's interacting proteins. Results The levels of YAP1 in tumor tissues were mostly lower than controls; Yap1 was ubiquitously expressed and located in cytosol; YAP1 is a significant predictor of survival in PAAD and KIRC; its expression is closely linked to immune infiltration; YAP1 exhibits a high mutation frequency across various cancer types; many phosphorylation sites especially S276 in Yap1 is highly a phosphorylation site; Yap1 interacts with proteins including Last1 and Last2 associated with the hypoxia pathway. Conclusion Yap1 is significantly associated with pan-cancer, which may serve as a potential biomarker of cancers.
Springer Science and Business Media LLC
Title: Role and mechanism of YAP1 in pan-cancer
Description:
Abstract Backgrounds and aims: Cancers threaten health and life of patients with tumors.
It is important to diagnose and treat various tumors as early as possible.
However, there is limited early biomarkers for cancers.
Yes-associated protein 1 (Yap1) is involved in the Hippo signaling pathway, and thus regulating development and cell growth.
Yap1’s role in pan-cancer remains to be investigated.
The objective of the present investigation was to explore the possible role and mechanism of Yap1 in pan-cancer.
Methods Timer2.
0 and GEPIA were employed to analyze the expression of YAP1 in cancerous tissues and controls; HPA was used to study the expression of YAP1 in different tissues and subcellular location; for survival analysis, GEPIA, the HPA, and KM plotter were utilized to generate survival curves, evaluating the prognostic significance of YAP1 expression; cBioPortal was used to investigate the mutation frequency and genetic alterations of YAP1; AlphaFold was applied to predict the structure of Yap1 and identify potential pathogenic sites, while PhosphoNet helped in predicting and analyzing phosphorylation sites of Yap1; the STRING was employed to explore Yap1's interacting proteins.
Results The levels of YAP1 in tumor tissues were mostly lower than controls; Yap1 was ubiquitously expressed and located in cytosol; YAP1 is a significant predictor of survival in PAAD and KIRC; its expression is closely linked to immune infiltration; YAP1 exhibits a high mutation frequency across various cancer types; many phosphorylation sites especially S276 in Yap1 is highly a phosphorylation site; Yap1 interacts with proteins including Last1 and Last2 associated with the hypoxia pathway.
Conclusion Yap1 is significantly associated with pan-cancer, which may serve as a potential biomarker of cancers.

Related Results

Abstract 1098: Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer
Abstract 1098: Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer
Abstract ROS1 gene arrangements occur in approximately 1% to 2% of non-small cell lung cancers. Crizotinib, the ROS1-tyrosine kinase inhibitor (TKI), has been approv...
Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study
Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study
Background: Yes-associated protein 1 (YAP1) is the main downstream effector of the Hippo signaling pathway, which is involved in tumorigenesis. This study aimed to comprehensively ...
Abstract 1819: The immunosuppressive role of YAP1 on the tumor immune microenvironment
Abstract 1819: The immunosuppressive role of YAP1 on the tumor immune microenvironment
Abstract Background and aims: Lung adenocarcinoma (LUAD), the most prevalent histologic subtype of non-small cell lung cancer, is one of the most fatal malignancies....
Cometary Physics Laboratory: spectrophotometric experiments
Cometary Physics Laboratory: spectrophotometric experiments
<p><strong><span dir="ltr" role="presentation">1. Introduction</span></strong&...
Abstract 1450: Global changes in RBPs and mRNA interactions during prostate cancer progression
Abstract 1450: Global changes in RBPs and mRNA interactions during prostate cancer progression
Abstract Prostate cancer (PC) is a leading cause of cancer in men in the United States and worldwide, disproportionately affecting men of African ancestry. The etiol...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

Back to Top